Infective complications in the renal transplant recipients


  • Giuseppina Rosso Azienda Usl Toscana Centro, S.O.C. Nefrologia e Dialisi, Firenze I ed Empoli, Nuovo Ospedale San Giovanni di Dio, Firenze – Italy
  • Maurizio Salvadori Professore di Nefrologia già Direttore Nefrologia e Trapianto, Azienda Ospedaliera Careggi, Firenze - Italy



Cytomegalovirus, Infection, Kidney transplantation, Polyomavirus, Recurrent/relapsing urinary tract infections


Infections remain a common complication of solid-organ transplantation and are a major factor of morbidity and mortality in renal transplant recipients.

The incidence of infection in renal transplant patients is directly related to the net immunosuppressive effect achieved and the duration of the administration of immunosuppressive therapy.

The major types of infections can be categorized according to the time post-transplant during which they occur: in the first month after transplantation post-surgical bacterial infections and in the period from one to four months post-transplant opportunistic infections, overall cytomegalovirus; late infections, beyond 6-12 months, are community-acquired infections.

Opportunistic infections (like Pneumocystis carini, Listeria monocytogenes, and Aspergillus fumigatus) most frequently occur in the first 12 months post-transplant and can be modulated by prior exposures and the use of prophylaxis.


Download data is not yet available.


Avery RK. Infectious disease following kidney transplant: core curriculum 2010. Am J Kidney Dis. 2010;55(4):755-771. PMID:20338466 DOI:

Bige N, Zafrani L, Lambert J, et al. Severe infections requiring intensive care unit admission in kidney transplant recipients: impact on graft outcome. Transpl Infect Dis. 2014;16(4):588-596. PMID:24966154 DOI:

Shen T-C, Wang I-K, Wei C-C, et al. The risk of septicemia in end-stage renal disease with and without renal transplantation: a propensity-matched cohort study. Medicine (Baltimore). 2015;94(34):e1437. PMID:26313801 DOI:

Dharnidharka VR, Agodoa LY, Abbott KC. Risk factors for hospitalization for bacterial or viral infection in renal transplant recipients--an analysis of USRDS data. Am J Transplant. 2007;7(3):653-661. PMID:17250559 DOI:

Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med. 1998;338(24):1741-1751. PMID:9624195 DOI:

Dorschner P, McElroy LM, Ison MG. Nosocomial infections within the first month of solid organ transplantation. Transpl Infect Dis. 2014;16(2):171-187. PMID:24661423 DOI:

Kaul DR, Vece G, Blumberg E, et al. Ten years of donor-derived disease: A report of the disease transmission advisory committee. [published online ahead of print July 5, 2020]. Am J Transplant. 2021;21(2):689-702. PMID:32627325 DOI:

Wolfe CR, Ison MG; AST Infectious Diseases Community of Practice. Donor-derived infections: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13547. PMID:30903670 DOI:

Miller R, Covington S, Taranto S, et al. Communication gaps associated with donor-derived infections. Am J Transplant. 2015;15(1):259-264. PMID:25376342 DOI:

van Delden C, Stampf S, Hirsch HH, et al; Swiss Transplant Cohort Study. Swiss Transplant Cohort Study : burden and timeline of infectious diseases in the first year after solid organ transplantation in the Swiss transplant cohort study. Clin Infect Dis. 2020;71(7):e159-e169. PMID:31915816 DOI:

Fishman JA, Gans H; AST Infectious Diseases Community of Practice. Pneumocystis jiroveci in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13587. PMID:31077616 DOI:

Sise ME, Goldberg DS, Kort JJ, et al. Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): an open-label study of combined glecaprevir and pibrentasvir to treat recipients of transplanted kidneys from deceased donors with hepatitis C virus infection. J Am Soc Nephrol. 2020;31(11):2678-2687. PMID:32843477 DOI:

Te H, Doucette K. Viral hepatitis: Guidelines by the American Society of Transplantation Infectious Disease Community of Practice. Clin Transplant. 2019;33(9):e13514. PMID:30817047 DOI:

Ison MG, Hirsch HH. Community-acquired respiratory viruses in transplant patients: Diversity, impact, unmet clinical needs. Clin Microbiol Rev. 2019;32(4):e00042-e19. PMID:31511250 DOI:

Le J, Durand CM, Agha I, Brennan DC. Epstein-Barr virus and renal transplantation. Transplant Rev (Orlando). 2017;31(1):55-60. PubMed. Google Scholar. PMID:28089555 DOI:

Allen UD, Preiksaitis JK. American Society of Transplantation Infectious Diseases Community of Practice : Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Disease Community of Practice. Clin Transplant. 2019;33:e13652. PMID:31230381 DOI:

Kasiske BL, Zeier MG, Chapman JR, et al; Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int. 2010;77(4):299-311. PMID:19847156 DOI:

Burns DM, Crawford DH. Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease. Blood Rev. 2004;18(3):193-209. PMID:15183903 DOI:

Kotton CN, Kumar D, Caliendo AM, et al; The Transplantation Society International CMV Consensus Group. The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2018;102(6):900-931. PMID:29596116 DOI:

Razonable RR, Humar A. Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13512. PMID:30817026 DOI:

Karadkhele G, Hogan J, Magua W, et al. CMV high-risk status and posttransplant outcomes in kidney transplant recipients treated with belatacept. Am J Transplant. 2021;21(1):208-221. PMID:32519434 DOI:

Humar A, Lebranchu Y, Vincenti F, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant. 2010;10(5):1228-1237. PMID:20353469 DOI:

Santos CA, Brennan DC, Fraser VJ, Olsen MA. Delayed-onset cytomegalovirus disease coded during hospital readmission after kidney transplantation. Transplantation. 2014;98(2):187-194. PMID:24621539 DOI:

Kean JM, Rao S, Wang M, Garcea RL. Seroepidemiology of human polyomaviruses. PLoS Pathog. 2009;5(3):e1000363. PMID:19325891 DOI:

Mallat SG, Tanios BY, Itani HS, et al. CMV and BKPyV infections in renal transplant recipients receiving an mTOR inhibitor-based regimen versus a CNI-based regimen: A systematic review and meta-analysis of randomized, controlled trials. Clin J Am Soc Nephrol. 2017;12(8):1321-1336. PMID:28576905 DOI:

Schaub S, Hirsch HH, Dickenmann M, et al. Reducing immunosuppression preserves allograft function in presumptive and definitive polyomavirus-associated nephropathy. Am J Transplant. 2010;10(12):2615-2623. PMID:21114642 DOI:

Johnston O, Jaswal D, Gill JS, Doucette S, Fergusson DA, Knoll GA. Treatment of polyomavirus infection in kidney transplant recipients: a systematic review. Transplantation. 2010;89(9):1057-1070. PMID:20090569 DOI:

Geetha D, Sozio SM, Ghanta M, et al. Results of repeat renal transplantation after graft loss from BK virus nephropathy. Transplantation. 2011;92(7):781-786. PMID:21836535 DOI:

Hollyer I, Ison MG. The challenge of urinary tract infections in renal transplant recipients. Transpl Infect Dis. 2018;20(2):e12828. PMID:29272071 DOI:

Senger SS, Arslan H, Azap OK, Timurkaynak F, Cağir U, Haberal M. Urinary tract infections in renal transplant recipients. Transplant Proc. 2007;39(4):1016-1017. PMID:17524879 DOI:

Säemann M, Hörl WH. Urinary tract infection in renal transplant recipients. Eur J Clin Invest. 2008;38(s2)(suppl 2):58-65. PMID:18826483 DOI:

Goldman JD, Julian K. Urinary tract infections in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13507. PMID:30793386 DOI:

Memikoğlu KO, Keven K, Sengül S, Soypaçaci Z, Ertürk S, Erbay B. Urinary tract infections following renal transplantation: a single-center experience. Transplant Proc. 2007;39(10):3131-3134. PMID:18089338 DOI:

Gyssens IC. Antibiotic policy. Int J Antimicrob Agents. 2011;38(suppl):11-20. PMID:22018989 DOI:

Tamma PD, Cosgrove SE. Antimicrobial stewardship. Infect Dis Clin North Am. 2011;25(1):245-260. PMID:21316003 DOI:

Baccarani U, Risaliti A, Adani GL, et al. Arterial rupture as the result of fungal arteritis after renal transplantation. Transplantation. 2003;76(1):266-269. PMID:12865825 DOI:

Laouad I, Buchler M, Noel C, et al. Renal artery aneurysm secondary to Candida albicans in four kidney allograft recipients. Transplant Proc. 2005;37(6):2834-2836. PMID:16182825 DOI:

Revankar SG, Hasan MS, Revankar VS, Sobel JD. Long-term follow-up of patients with candiduria. Eur J Clin Microbiol Infect Dis. 2011;30(2):137-140. PMID:20857164 DOI:



How to Cite

Rosso, G., & Salvadori, M. (2024). Infective complications in the renal transplant recipients. Giornale Di Clinica Nefrologica E Dialisi, 36(1), 1–6.



Original articles


Received 2023-12-27
Accepted 2024-01-11
Published 2024-02-26


Most read articles by the same author(s)

1 2 > >>